

G Literaturverzeichnis

Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M. G., Truss, M., Beato, M., Sica, V., Bresciani, F. and Weisz, A. (1996): 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and 105 Rb phosphorylation during mitogenic stimulation of g(1)-arrested human breast cancer cells. *Oncogene* 12(11): 2315-24.

Altucci, L., Addeo, R., Cicatiello, L., Germano, D., Pacilio, C., Battista, T., Cancemi, M., Petrizzi, V. B., Bresciani, F. and Weisz, A. (1997): Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5 and 6 and increases cyclin mRNA expression in rat uterus. *Endocrinology* 138(3): 978-984.

Andersson, M., Storm, H. H. and Mouridsen, H. T. (1991): Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. *J.Natl.Cancer Inst.* (83): 1013-1017.

Angerer, von E. (1996): Entwicklungsstrategien für Arzneistoffe zur Therapie hormonabhängiger Tumoren. *Pharm.unserer Zeit* (2), 74-84.

AWMF Leitlinien-Register Nr. 032/034: Endometriumkarzinom. In: *Kurzgefaßte interdisziplinäre Leitlinien 2000* (B22), 287 ff.

Baniahmad, C., Nawaz, Z., Baniahmad, A., Gleeson, M. A., Tsai, M. J. and O'Malley, B. W. (1995): Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. *Mol.Endocrinol.* 9(1): 34-43.

Beato, M. (1989): Gene regulation by steroid hormones. *Cell* 56(3): 335-344.

Beatson, G. T. (1896): On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. *Lancet* (ii): 171-175.

Becher, R. (1986): In: Höffken, H, (Hrsg.): *Aktuelle Aspekte der Hormontherapie des Mammakarzinoms*, Enke-Verlag.

Bernstein, L., Deapen, D., Cerhan, J. R., Schwartz, S. M., Liff, J., McGann-Maloney, E., Perlman, J. A. and Ford, L. (1999): Tamoxifen therapy for breast cancer and endometrial cancer risk. *J.Natl.Cancer Inst.* 91(9): 1654-1662.

Berry, M., Metzger, D. and Chambon, P. (1990): Role of the two activating domains of the oestrogen receptor in the cell-type and promotor-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. *EMBO J.* (9): 2811-2818.

Berthois, Y., Dong, X. F. and Martin, P. M. (1989): Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. *Biochem.Biophys.Res.Commun.* 159(1): 126-31.

- Berthois, Y., Katzenellenbogen, J. A. and Katzenellenbogen, B. S. (1986):** Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen responsive cells in culture. *Proc.Natl.Acad.Sci.USA* (83): 2496-2500.
- Bindal, R. D. and Katzenellenbogen, J. A. (1988):** Bis(4-hydroxyphenyl) [2-(phenoxy-sulfonyl) phenyl] methane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein). *J.Med.Chem.* (31): 1978-1983.
- Bonkhoff, H., Fixemer, T., Hunsicker, I. and Remberger, K. (1999):** Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. *Am.J.Pathol.* 155(2): 641-7.
- Boyd, M. R. and Paull, K. D. (1995):** Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. *Drug Dev.Res.* (34): 91-109.
- Bristow, R. E. (1999):** Endometrial cancer. *Curr.Opin.Oncol.* 11(5): 388-393.
- Brooks, S. C., Locke, E. R. and Soule, H. D. (1973):** Estrogen receptors in a human cell line (MCF-7) from breast carcinoma. *J.Biol.Chem.* (248): 6251-6253.
- Burckhardt, P. (1999):** Selective estrogen receptor modulators (SERM): neue Substanzen für die Hormonersatztherapie. *Schweiz.Med.Wochenschr.* (129): 1926-30.
- Carroll, J. S., Prall, O. W., Musgrove, E. A. and Sutherland, R. L. (2000):** A pure anti-estrogen antagonist inhibits cyclin E-cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. *J.Biol.Chem.* 275(49): 38221-9.
- Castelbaum, A. J., Ying, L., Somkuti, S. G., Sun, J., Ilesanmi, A. O. and Lessey, B. A. (1997):** Characterization of integrin expression in a well differentiated endometrial adenocarcinoma cell line (Ishikawa). *J.Clin.Endocrinol.Metab.* 82(1): 136-42.
- Catherino, W. H., Wolf, D. M. and Jordan, V. C. (1995):** A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. *Mol.Endocrinol.* 9(8): 1053-1063.
- Ciocca, D. R., Stati, A. O. and Amprino de Castro, M. M. (1990):** Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. *Breast Cancer Res.Treat.* 16(3): 243-251.
- Clarke, R. (1996):** Animal models of breast cancer: their diversity and role in biomedical research. *Breast Cancer Res.Treat.* (39): 1-6.
- Compton, M. M. (1992):** A biochemical hallmark of apoptosis: internucleosomal degradation of the genome. *Cancer and Metastasis Reviews* 11(2): 105-119.

- Dallenbach-Hellweg, G. (1981):** Die Tumoren. In: Dallenbach-Hellweg, G. (Hrsg.) Endometrium. Pathologische Histologie in Diagnostik und Forschung (2.Auflage), Springer-Verlag (C-4), 157-214.
- Dana, S. L., Hoener, P. A., Wheeler, D. A., Lawrence, C. B. and McDonnell, D. P. (1994):** Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens mammalian cells. *Mol.Endocrinol.* (8): 1193-1207.
- Dardes, R. C., Bentrem, D., O'Regan, R. M., MacGregor Schafer, J. and Jordan, V. C. (2001):** Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. *Clin.Cancer Res.* (7): 4149-4155.
- Dardes, R. C., O'Regan, R. M., Gajdos, C., Robinson, S. P., Bentrem, D., Reyes, de los A. and Jordan, V. C. (2002):** Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. *Clin.Cancer Res.* (8): 1995-2001.
- Dauvois, S., Danielian, P. S., White, R. and Parker, M. G. (1992):** Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. *Proc.Natl.Acad.Sci.USA* (89): 4037-4041.
- DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F., Saunders, C., Baum, M., Walton, P., Sutcliffe, F. and Wakeling, A. E. (1994):** Investigations of new pure antiestrogen (ICI 182780) in women with primary breast cancer. *Cancer Res.* (54): 408-414.
- Dickson, R. B. and Lippman, M. E. (1988):** Control of human breast cancer by estrogen, growth factors, and oncogenes. In: Lippman, M. E. & Dickson, R. B. (Hrsg.) *Breast cancer: Cellular and molecular biology*, Boston: Kluwer, 119-165.
- Diel, P., Smolnikar, K. and Michna, H. (1999):** The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. *Breast Cancer Res.Treat.* 58(2): 87-97.
- Dowsett, M., Howell, R., Salter, J., Thomas, N. M. and Thomas, E. J. (1995):** Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrial in vivo. *Hum.Reprod.* 10(2): 262-267.
- Dunn, O. J. (1964):** Multiple comparisons using rank sums. *Technometrics* 6(3): 241-252.
- Emons, G. and Heyl, W. (2000):** Hormonal treatment of endometrial cancer. *J.Cancer Res.Clin.Oncol.* (126): 619-623.

- Emons, G. and Schulz, K.D. (1998):** Ätiologie des Endometriumkarzinoms. In: Römer, T. & Mueck, A. O. (Hrsg.), Endometrium und Hormonsubstitution, Stuttgart New York: Thieme, 47-54.
- Emons, G., Fleckenstein, G., Hinney, B., Huschmand, A. and Heyl, W. (2000):** Hormonal interactions in endometrial cancer. *Endocr.Relat.Cancer* (7): 227-242.
- Enmark, E. and Gustafsson, J.-Å. (1998):** Characterization of human estrogen receptor β . In: Gronemeyer, H., Fuhrmann, U. and Parczyk, K. (Hrsg.) Molecular basis of sex hormone receptor function, Springer Verlag, (3), 161-177.
- Ercoli, A., Scambia, G., Fattorossi, A., Raspaglio, G., Battaglia, A., Cicchillitti, L., Malorni, W., Rainaldi, G., Benedetti Pancini, P. and Mancuso, S. (1998):** Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line: *Int.J.Cancer* 76(1): 47-54.
- Evans, R. M. (1988):** The steroid and thyroid hormone receptor superfamily. *Science* (240): 889-895.
- Fitzpatrick, S. L., Brightwell, J., Wittliff, J. L., Barrows, G. H. and Schultz, G. S. (1984):** Epidermal growth factor binding by breast biopsies and relationship to estrogen receptor and progesterin receptor levels. *Cancer Res.* (44): 3448-3453.
- Friedl, A. and Jonat, W. (1989):** Antiöstrogenbindungsstellen beim Mammakarzinom. In: Meerpohl, H. G., Kaufmann, M., Alt, D. & Pfeleiderer, A. (Hrsg.) Aktuelle Onkologie 46, Antiöstrogene in Forschung und Klinik. W. Zuckschwerdt Verlag München, 27-33.
- Furr, B. J. A. and Jordan, V. C. (1984):** The pharmacology and clinical uses of tamoxifen. *Pharmacol.Ther.* (25): 127-205.
- Gavrieli, Y., Sherman, Y. and Ben-Sasson, S. A. (1992):** Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J.Cell Biol.* (119), 493-501.
- Gerdes, J., Lemke, H., Baisch, H, Wacker, H.-H., Schwab, U. and Stein, H. (1984):** Cell cycle analysis of cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J.Immunol.* (133): 1710-1715.
- Gibson, M. K., Nemmers, L. A., Beckmann, W. C., Davis, V. L., Curtis, S. W. and Korach, K. S. (1991):** The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. *Endocrinology* 129(4): 2000-2100.
- Gillies, R. J., Didier, N. and Denton, M. (1986):** Determination of cell number in monolayer Cultures. *Anal.Biochem.* (159), 109-113.

- Gong, Y., Ballejo, G., Murphy, L. C. and Murphy, L. J. (1992):** Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells. *Cancer Res.* 52(7): 1704-1709.
- Gottardis, M. M., Ricchio, M. E., Satyswaroop, P. G. and Jordan, V. C. (1990):** Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa 101) in athymic mice. *Cancer Res.* 50(11): 3189-3192.
- Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G. and Jordan, V. C. (1988):** Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. *Cancer Res.* (48): 812-815.
- Graham, J. D., Bain, D. L., Richer, J. K., Jackson, T. A., Tung, L. and Horwitz, K. B. (2000):** Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? *J.Steroid.Biochem.Mol.Biol.* 74(5): 255-9.
- Gronemeyer, H. and Laudet, V. (1995):** Transcription factors 3: nuclear receptors. *Protein Profile* 2(11): 1173-1308.
- Gronemeyer, H., Benhamou, B., Berry, M., Bocquel, M. T., Gofflo, D., Garcia, T., Lerouge, T., Metzger, D., Meyer, M. E. and Tora, L. (1992):** Mechanisms of antihormon action. *J.Steroid.Biochem.Mol.Biol.* (41): 217-221.
- Guerin, T.F., Mondido, M., McClenn, B. and Peasley, B. (2001):** Application of resazurin for estimating abundance of contaminant-degrading micro-organisms. *Lett.Appl.Microbiol.* 32(5): 340-345.
- Gusberg, S. B. (1990):** Tamoxifen for breast cancer: Associated endometrial cancer. *Cancer* (65): 1463-1464.
- Hachisuga, T., Hideshima, T., Kawarabayashi, T., Eguchi, F., Emoto, M. and Shirakusa, T. (1999):** Expression of steroid receptors, Ki67, and epidermal growth factor receptor in tamoxifen-treated endometrium. *Int.J.Gynecol.Pathol.* 18(4): 297-303.
- Hackenberg, R., Hawighorst, T., Hild, F. and Schulz, K-D. (1997):** Establishment of new epithelial carcinoma cell lines by blocking monolayer formation. *J.Cancer Res.Clin.Oncol.* (123), 669-673.
- Harper, M. J. K. and Walpole, A. L. (1967):** Mode of action of ICI 46,474 in preventing implantation in rats. *J.Endocrinol.* (37): 83-92.
- Hendricks, D. T., Taylor, R., Reed, M. and Birrer, M. J. (1997):** FHIT gene expression in human ovarian, endometrial and cervical cancer cell lines. *Cancer Res.* 57(11): 2112-5.
- Hickman, J. A. (1992):** Apoptosis induced by anticancer drugs. *Cancer Metastasis Rev.* 11(2): 121-139.

- Hoffmann, J., Bohlmann, R., Heinrich, N., Hofmeister, H., Kroll, J., Künzer, H., Lichtner, R. B., Nishino, Y., Parczyk, K., Sauer, G., Schneider, M. R. (2000):** Treatment with the pure antiestrogen ZK 191703 results in long term growth repression of estrogen-sensitive or tamoxifen-resistant human breast cancer models xenografted in immunodeficient mice. *Clin.Cancer Res.* (6S): 492.
- Holst, von T. (2000):** Alternativen zur Hormonersatztherapie: Raloxifen und Tibolon. *Z.Ärztl.Fortbild.Qualitätssich.* 94(3): 205-9.
- Horn, D. W., Vollmer, G., Deerberg, F. and Schneider, M. R. (1993):** The EnDA endometrial adenocarcinoma: an oestrogen-sensitive, metastasizing, in vivo tumour model of the rat. *J.Cancer Res.Clin.Oncol.* 119(8): 450-6.
- Horwitz, K. B. and McGuire, W. L. (1975):** Progesterone receptors in human breast cancer. *Steroids* (25): 497-505.
- Horwitz, K. B. and McGuire, W. L. (1978):** Estrogen control of progesterone receptor in human breast cancer. *J.Biol.Chem.* (253): 2223-2228.
- Horwitz, R. I., Feinstein, A. R., Horwitz, S. M. and Robboy, S. J. (1981):** Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies. *Lancet* (2): 66-68.
- Housley, P. R., Sanchez, E. R., Danielsen, M., Ringold, G. M. and Pratt, W. B. (1990):** Evidence that the conserved region in the steroid binding domain of the glucocorticoid receptor is required for both optimal binding of hsp90 and protection from proteolytic cleavage. A two-site model for hsp90 binding to the steroid binding domain. *J.Biol.Chem.* 265(22): 12778-81.
- Howell, A., Osborne, C. K., Morris, C. and Wakeling, A. E. (2000):** ICI 182780 (Faslodex): development of a novel , pure antiestrogen. *Cancer* 89(4): 817-25.
- Iwashita, I., Ueyama, T., Iwashita, A., Kawamoto, K., Kitagawa, S., Motooka, M., Utsunomiya, T. and Masuda, K. (1998):** Natural history of colorectal carcinoma: can the tumor volume doubling time be predicted by radiologic findings or immunohistochemical variables? *J.Surg.Oncol.* 68(4): 215-224.
- Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A. and Hortobagyi, G. N. (1995):** Use of tamoxifen for breast cancer twenty eight years later. *J.Clin.Oncol* 13(2): 513-529.
- Jamil, A., Croxtall, J. D. and White, J. O. (1991):** The effect of antioestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). *J.Mol.Endocrinol.* 6(3): 215-221.

- Jänne, O., Kaupilla, A., Kontula, K., Syrjälä, P. and Vihko, R. (1979):** Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. *Int.J.Cancer* (24): 545-554.
- Jazaeri, O., Shupnik, M. A., Jazaeri, A. A. and Rice, L. W. (1999):** Expression of estrogen receptor α mRNA and protein variants in human endometrial carcinoma. *Gynecol.Oncol.* (74): 38-47.
- Johnston, S. R. D., Boeddinghaus, I. M., Riddler, S., Haynes, B. P., Hardcastle, I. R., Rowlands, M., Grimshaw, R., Jarman, M. and Dowsett, M. (1999):** Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. *Cancer Res.* 59(15): 3646-3651.
- Jordan, V. C. (1988):** The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. *Breast Cancer Res.Treat.* (11): 197-209.
- Kaupilla, A., Isotalo, H. E., Kivinen, S. T. and Vihko, R. K. (1986):** Prediction of clinical outcome with oestrogen and progestin receptor concentrations and their relationship to clinical and histopathological variables in endometrial cancer. *Cancer Res.* (46): 5380-5384.
- Khalifa, M. A., Abdoh, A. A., Mannel, R. S., Haraway, S. D., Walker, J. L. and Min, K.-W. (1994):** Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. *Cancer* 73(2): 370-376.
- King, R. J. B., Raju, K. S. and Taylor, R. W. (1986):** Progestin effects on normal and neoplastic human endometrium. In: Schulz, K.-D., King, R. J., Pollow, K. & Taylor, R. W. (Hrsg.) *Endometrial cancer*, Zuckschwerdt Verlag, München, 46-51.
- Kraus, W. L. and Katzenellenbogen, B. S. (1993):** Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. *Endocrinology* 132(6): 2371-2379.
- Kueng, W., Silber, E. and Eppenberger, U. (1989):** Quantification of cells cultured on 96-well plates. *Anal.Biochem.* (182): 16-19.
- Kumar, V. and Chambon, P. (1988):** The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. *Cell* (55): 145-156.
- Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.-R. and Chambon, P. (1987):** Functional domains of the human estrogen receptor. *Cell* (51): 941-951.
- Kurebayashi, J., Otsuki, T., Yamamoto, S. Kurosumi, M., Nakata, T., Akinaga, S. and Sonoo, H. (1998):** A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro. *Oncology* 55(Suppl.1): 23 – 34.

- Lancaster, M. V. and Fields, R. D. (1996):** Antibiotic and cytotoxic drug susceptibility assays using resazurin and poisoning agents. U.S. Patent No. 5, 501, 959.
- Lessey, B. A., Ilesanmi, A. O., Castelbaum, A. J., Yuan, L., Somkuti, S. G., Satyawaroop, P. G. and Chwalisz, K. (1996):** Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alpha 1 integrin. *J.Steroid Biochem.Mol.Biol.* 59 (1), 31-39.
- Levenson, A. S. and Jordan, V. C. (1998):** The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. *Cancer Res.* (58): 1872-1875.
- Lichtner, R. B., Parczyk, K., Birchmeier, W. and Schneider, M. R. (1999):** Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines. *J.Steroid Biochem.Mol.Biol.* (71):181-189.
- Lippman, M. E., Bolan, G. and Huff, K. (1976):** The effects of estrogens and antiestrogens on hormone responsive human breast cancer cells in long-term tissue culture. *Cancer Res.* (36): 4595-4601.
- Liu, H., Lee, E. S., Deb Los Reyes, A., Zapf, J. W. and Jordan, V. C. (2001):** Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. *Cancer Res.* 61(9): 3632-9.
- Llorens, M. A., Bermejo, M. J., Salcedo, M. C., Charro, A. L. and Puente, M. (1989):** Epidermal growth factor receptors in human breast and endometrial carcinomas. *J.Steroid Biochem.* (34): 505-509.
- Lower, E. E., Blau, R., Gazder, P. and Stahl, D. L. (1999):** The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. *Breast Cancer Res.Treat.* (58): 205-211.
- McLeskey, S. W., Zhang, L., El-Ashry, D., Trock, B. J., Lopez, C. A., Kharbanda, S., Tobias, C. A., Lorant, L. A., Hannum, R. S., Dickson, R. B. and Kern, F. G. (1998):** Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. *Clin.Cancer Res.* 4(3): 697-711.
- Meggouh, F., Lointier, P. and Saez, S. (1991):** Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. *Cancer Res.* (51): 1227-1233.
- Miralles, F., Gaudalet, C., Cavailles, V., Rochefort, H. and Augereau, P. (1994):** Insensitivity of cathepsin D gene to estradiol in endometrial cells is determined by the sequence of its estrogen response element. *Biochem.Biophys.Res.Comm.* 203(1): 711-718.

- Mukku, V. R. and Stancel, G. M. (1985):** Regulation of epidermal growth factor receptor by estrogen. *J.Biol.Chem.* 260(17): 9820-4.
- Murphy, L. J. (1994):** Growth factors and steroid hormone action in endometrial cancer *J.Steroid.Biochem.Molec.Biol.* 48(5/6): 419-423.
- Niikura, H., Sasano, H., Matsunaga, G., Watanabe, K., Ito, K., Sato, S. and Yajima, A. (1995):** Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. *Hum.Pathol.* 26(8): 892-896.
- O'Regan, R. M., Cisneros, A., England, G. M., MacGregor, J. I., Muenzner, H. D., Assikis, V. J., Bilimoria, M. M., Piette, M., Dragan, Y. P., Pitot, H. C., Chatterton, R. and Jordan, V. C. (1998):** Effects of the antiestrogens tamoxifen, toremifene, and ICI 182780 on endometrial cancer growth. *J.Natl.Cancer Inst.* (90): 1552-1557.
- Osborne, C. K., Boldt, D. H. and Estrada, P. (1984):** Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. *Cancer Res.* 44(4): 1433-1439.
- Osborne, M. P. (1999):** Breast cancer prevention by antiestrogens. *Ann.N.Y.Acad. Sci.* (889): 146-151.
- Parker, M. G., Heery, D., Kalkhoven, E. and Valentine J. (1998):** Role of coactivators in transcriptional activation by estrogen receptors. In: Gronemeyer, H., Fuhrmann, U and Parczyk, K. (Hrsg.) *Molecular basis of sex hormone receptor function*, Springer Verlag, (3), 53-61.
- Pennisi, E. (2000):** A mouse chronology. *Science* 288(5464): 248-257.
- Philipson, K. A., Elder, M. G. and White, J. O. (1985):** The effects of medroxyprogesterone acetate on enzyme activities in human endometrial carcinoma. *J.Steroid.Biochem.* (23): 1059-1064.
- Pratt, W. B. and Toft, D. O. (1997):** Steroid receptor interaction with heat shock protein and immunophilin chaperones. *Endocr.Rev.* 18(3): 306-360.
- Reddy, K. V., Meherji, P. K., Gokral, J. S. and Shahani, S. K. (1997):** Resazurin reduction test to evaluate semen quality. *Indian J.Exp.Biol.* 35(4): 369-373.
- Reynolds, R. K., Hu, C. and Baker, V. V. (1998):** Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines. *Gynecol.Oncol.* 70(2): 202-9.
- Reynolds, R. K., Owens, C. A. and Roberts, J. A. (1996):** Cultured endometrial cancer cells exhibit autocrine growth factor stimulation that is not observed in cultured normal endometrial cells. *Gynecol.Oncol.* 60(3): 380-6.

- Ricci, M. S., Toscano, D. G. and Toscano jr., W. A. (1999):** ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function. *In Vitro Cell.Dev.Biol.-Animal* (35): 183-189.
- Robertson, J. A., Zhang, Y. and Ing, N. H. (2001-a):** ICI 182,780 acts as a partial agonist and antagonist of estradiol effects in specific cells of the sheep uterus. *J.Steroid.Biochem.Mol.Biol.* (77): 281-287.
- Robertson, J. F., Nicholson, R. I. Bundred, N. J., Anderson, E., Rayter, Z., Dowsett, M., Fox, J. N., Gee, J. M., Webster, A., Wakeling, A. E., Morris, C. and Dixon, M. (2001-b):** Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. *Cancer Res.* 61(18): 6739-46.
- Romeis (1989):** Doppelfärbung mit HE. In: P. Böck (Hrsg.) *Mikroskopische Technik*, 17. Auflage, Urban&Schwarzenberg-Verlag, 235.
- Sainsbury, J. R. C., Farndon, J. R., Sherbert, G. V. and Harris, A. L. (1985):** Epidermal growth factor receptors and estrogen receptors in human breast cancer. *Lancet* (1): 364-366.
- Satyaswaroop, P. G. and Tabibzadeh, S. S. (1991):** Extracellular matrix and the pattern of differentiation of human endometrial carcinomas in vitro and in vivo. *Cancer Res.* 51 (20): 5661-6.
- Satyaswaroop, P. G., Zaino, R. J. and Mortel, R. (1983):** Human endometrial adenocarcinoma transplanted into nude mice: growth regulation by estradiol. *Science* 219 (7): 58-60.
- Satyaswaroop, P. G., Zaino, R. J. and Mortel, R. (1984):** Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. *Cancer Res.* 44(9): 4006-4010.
- Satyaswaroop, P. G., Zaino, R. J., Clarke, C. L. and Mortel, R. (1987):** Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma. *J.Steroid Biochem.* 27(1-3): 431-438.
- Scambia, G., Ferrandina, G., D'Agostino, G., Fagotti, A., Di Stefano, M., Fanfani, F., Serri, F. G. and Mancuso, S. (1998):** Oestrogen and progesterone receptors in ovarian carcinoma. *Endocr.Relat.Cancer* (5): 293-301.
- Schilli, M. B., Paus, R. and Menrad, A. (1998):** Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. *J.Invest.Dermatol.* 111(4): 598-604.
- Schneider, M. R. (1995):** Hormonale Therapie maligner Tumoren. In: Zeller WJ & zur Hausen H (Hrsg.) *Onkologie: Grundlagen-Diagnostik-Therapie-Entwicklung*, ecomed Landsberg/Lech (IV-5), 1-39.

- Smith, D. F. and Toft, D. O. (1993):** Steroid receptors and their associated proteins. *Mol.Endocrinol.* 7(1): 4-11.
- Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. and Klenk, D. C. (1985):** Measurement of protein using bicinchoninic acid. *Anal.Biochem.* (150): 76-85.
- Somkuti, S. G., Yuan, L., Fritz, M. A. and Lessey, B. A. (1997):** Epidermal growth factor and sex steroid dynamically regulate a marker of endometrial receptivity in Ishikawa cells. *J.Clin.Endocrinol.Metab.* 82(7): 2192-2197.
- Soule, H. D., Vazquez, J., Long, A., Albert, S. and Brennan, M. (1973):** A human cell line from a pleural effusion derived from a breast carcinoma. *J.Natl.Cancer Inst.* (51): 1409-1416.
- Spector, D. L., Goldman, R. D. and Leinwand, L. A. (1998):** DNA content. In: Spector, D. L., Goldman, R. D. and Leinwand, L. A. (Hrsg.) *Cells. A Laboratory Manual*, Cold Spring Harbor Laboratory Press (Vol.1), 16.3-16.6.
- Sporn, M. B. and Torado, G. J. (1980):** Autocrine secretion and malignant transformation of cells. *N.Engl.J.Med.* (303): 878-880.
- Stackievicz, R., Drucker, L., Radnay, J., Beyth, Y., Yarkoni, S. and Cohen, I. (2001):** Tamoxifen modulates apoptotic pathways in primary endometrial cell cultures. *Clin.Cancer Res.* (7): 415-420.
- Stryer, L. (1987 -a):** Chromosomen und Genexpression in Eukaryoten. In: Stryer, L. (Hrsg.) *Biochemie*, 4. Auflage, Spektrum Akademischer Verlag GmbH (33), 878 und 1036.
- Stryer, L. (1987 -b):** Hormonwirkung. In: Stryer, L. (Hrsg.) *Biochemie*, 4. Auflage, Spektrum Akademischer Verlag GmbH (33), 1013 und 1035.
- Sutherland, R. L., Reddel, R. R. and Green, M. D. (1983):** Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antiestrogens. *Eur.J.Cancer Clin.Oncol.* (19): 307-318.
- Taketani, Y. and Mizuno, M. (1988):** Cyclic changes in epidermal growth factor receptor in human endometrium during menstrual cycle. *Endocrinol.Jpn.* 35(1): 19-25.
- Tonetti, D. A., O'Regan, R., Tanjore, S., England, G. and Jordan, V. C. (1998):** Anti-estrogen stimulated human endometrial cancer growth: laboratory and clinical considerations. *J. Steroid.Biochem.Mol.Biol.* (65): 181-189.
- Towbin, H., Staehelin, T. and Gordon, J. (1979):** Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. *Proc.Natl.Acad.Sci.* (76): 4350-4354.

- Treon, S. P., Teoh, G., Urashima, M., Ogata, A., Chauhan, D., Webb, I. J. and Anderson, K. C. (1998):** Anti-estrogens induce apoptosis of multiple Myeloma cells. *Blood* 92(5): 1749-1757.
- Tzukerman, M. T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M. G., Stein, R. B., Pike, J. W. and McDonnell, D. P. (1994):** Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. *Mol.Endocrinol.* (8): 21-30.
- Wakelin, L. P., Adams, A., Hunter, C. and Waring, M. J. (1981):** Interaction of crystal violet with nucleic acid. *Biochemistry* 20 (20): 5779-87.
- Wakeling, A. E. (1989):** Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. *J.Steroid Biochem.* 34(1): 183-188.
- Wakeling, A. E. (1993):** The future of new pure antiestrogens in clinical breast cancer. *Breast Cancer Res.Treat.*(25): 1-9.
- Wakeling, A. E. (1994):** A new approach to breast cancer therapy- Total estrogen ablation with pure antiestrogens. In: Jordan, V. C. (Hrsg.), Long-term tamoxifen treatment for breast cancer. Madison, WI, University of Wisconsin, 219-234.
- Wakeling, A. E. and Bowler, J. (1992):** ICI 182,780, a new antiestrogen with clinical potential. *J.Steroid.Biochem.Mol.Biol.* 43(1-3): 173-177.
- Wakeling, A. E., Dukes, M. and Bowler, J. (1991):** A potent specific pure antiestrogen with clinical potential. *Cancer Res.* (51): 3867-3873.
- Wang, D.-P., Konishi, I., Koshiyama, M., Mandai, M., Nanbu, Y., Ishikawa, Y., Mori, T. and Fujii, S. (1993):** Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas. *Cancer* 72(9): 2628-2637.
- Watson, H., Franks, S. and Bonney, R. C. (1994):** The epidermal growth factor receptor in the human endometrial adenocarcinoma cell line HEC-1-B. *J.Steroid Biochem.Mol.Biol.* 51(1/2): 41-45.
- Watts, C. K. W., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E. A. and Sutherland, R. L. (1995):** Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. *Mol Endocrinol.* (9): 1804-1813.
- Webster, N. J. G., Green, S., Jin, J.-R. and Chambon, P. (1988):** The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. *Cell* (54): 199-207.

- Wehner, R. and Gehring, W. (1990):** Struktur und Funktion der Zelle. In: Zoologie, Thieme-Verlag: 38-40.
- Weiderpass, E., Adami, H.-O., Baron, J. A., Magnusson, C., Bergström, R., Lindgren, A., Correia, N. and Persson, I. (1999):** Risk of endometrial cancer following estrogen replacement with and without progestins. *J.Natl.Cancer Inst.* 91(13): 1131-1137.
- White, J. O., Owen, G. I., De Clercq, N. A. M. and Soutter, W. P. (1993):** Antiestrogens in the treatment of endometrial cancer. *Endocr.Relat.Cancer* (44): 47-57.
- Wilcken, N. R., Prall, O. W., Musgrove, E. A. and Sutherland, R. L. (1997):** Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. *Clin.Cancer Res.* 3(6): 849-854.
- Wilcken, N. R., Sarcevic, B., Musgrove, E. A. and Sutherland, R. L. (1996):** Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. *Cell Growth Differ.* (7): 65-74.
- Wyld, K. D., Chester, J. D. and Perren, T. J. (1998):** Endocrine aspects of the clinical management of breast cancer-current issues. *Endocr.Relat.Cancer* (5): 97-100.
- Yang, N. N., Venugopalan, M., Hardikar, S. and Glasebrook, A. (1997):** Raloxifene response needs more than an element. *Science* (275): 1249.
- Zaino, R. J., Satyaswaroop, P. G. and Mortel, R. (1985):** Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. *Cancer Res.* (45): 539-541.
- Zarcone, R., Bellini, P., Cardone, G., Vicinanza, G. and Cardone, A. (1995):** Epidermal growth factor receptor expression: is it the same in normal and malignant endometria? *Clin.Exp.Obstet.Gynecol.* 22(4): 298-300.